SubHero Banner

Esperoct® (antihemophilic factor [recombinant], glycopegylated-exei) – New drug approval

February 19, 2019 - Novo Nordisk announced the FDA approval of Esperoct (antihemophilic factor [recombinant], glycopegylated-exei), for use in adults and children with hemophilia A for: on-demand treatment and control of bleeding episodes; perioperative management of bleeding; and routine prophylaxis to reduce the frequency of bleeding episodes.

Download PDF